Basel, Switzerland – The Korea Trade-Investment Promotion Agency (KOTRA), in strategic partnership with Pohang City, made a significant push to showcase the burgeoning Korean biotechnology sector at the prestigious Swiss Biotech Day 2025, held in Basel from May 5th to 6th. Their joint efforts included the operation of a dedicated Korean Pavilion and the hosting of the 'Korea-Switzerland Biohealth Partnership' forum, a dynamic platform designed to foster collaborations through partnering consultations and insightful discussions.
This initiative comes at a crucial juncture for the Korean pharmaceutical and biotechnology industry. The traditionally dominant US market is experiencing a period of rapid transformation, driven by evolving healthcare policies and increasingly stringent regulations. This shifting landscape has turned the spotlight towards Europe as a vital alternative, offering Korean companies promising avenues for export diversification and the cultivation of strategic partnerships.
Switzerland, in particular, stands out as a nucleus of global biohealth innovation. The Alpine nation is home to the global headquarters of two of the world's top ten pharmaceutical giants, Roche and Novartis, alongside Lonza, the undisputed leader in Contract Development and Manufacturing Organization (CDMO) services. This concentration of industry power, encompassing over 1,200 specialized companies, underscores Switzerland's pivotal role in the global biopharmaceutical ecosystem. The economic significance of this sector is undeniable, with pharmaceutical and biological products constituting over one-third of Switzerland's total exports, highlighting its advanced research capabilities and manufacturing prowess.
Swiss Biotech Day has firmly established itself as Europe's premier biotech event, acting as a vital conduit for networking and deal-making among pharmaceutical and biotech executives, researchers, investors, and policymakers. The 12th iteration of this influential gathering witnessed the participation of approximately 2,500 delegates from 40 countries, engaging in a rich program featuring cutting-edge seminars, insightful panel discussions, and dynamic startup pitching sessions.
Capitalizing on this high-profile platform, KOTRA and Pohang City established a prominent national pavilion within the event's 'Global Village.' This strategic presence facilitated dedicated partnering consultations aimed at bolstering the export potential and fostering joint research and development (R&D) collaborations for 15 innovative Korean biohealth companies. The two-day event saw an impressive exchange, with over 200 individual consultations taking place, paving the way for potential synergistic relationships with numerous European and Swiss enterprises.
Among the participating Korean companies, ILIAS Biologics garnered significant attention. Specializing in the development of novel therapeutics for inflammatory diseases and central nervous system (CNS) disorders based on its proprietary exosome platform technology, ILIAS Biologics was recognized as a promising startup. This recognition culminated in a valuable opportunity to present their groundbreaking work on the official stage, enhancing their visibility among potential investors and partners.
Further amplifying the collaborative spirit, KOTRA, in conjunction with Pohang City and the Embassy of the Republic of Korea in Switzerland, jointly hosted the 'Korea-Switzerland Biohealth Partnership' forum. This dedicated session provided a platform for Korean companies to showcase their cutting-edge technologies to a discerning audience of Swiss and European bio companies and research institutions. A highlight of the forum was the presentation by Swiss-based Topadur Pharma, which shared the successful outcomes of its collaborative project with a Korean company under the 'KIAT-Swiss Innovation Agency R&D Support Program.' This real-world example served as a compelling model for future bilateral research and development endeavors.
Extending their engagement beyond the formal event, KOTRA, in partnership with Switzerland Global Enterprise (S-GE), the official Swiss agency for export and investment promotion, organized a series of insightful visits to key Swiss research and innovation hubs on May 7th. These visits included prominent institutions such as the Basel Innovation Center, Bio-Technopark Zurich, the research institute of Inselspital (University Hospital of Bern), Visp BioArk (a dynamic biotech park in Valais), the École Polytechnique Fédérale de Lausanne (EPFL), a world-renowned science and technology university, and the Biopôle Lausanne cluster, a vibrant life sciences campus. These site visits provided invaluable opportunities for Korean delegates to gain firsthand insights into the Swiss biotech ecosystem, explore potential research collaborations, and understand the support infrastructure available to biotech companies in Switzerland.
Chae Kyung-ho, Head of the KOTRA Zurich Trade Office, underscored the strategic importance of such European on-the-ground events for Korean companies, stating, "Swiss Biotech Day and similar European platforms offer a crucial springboard for Korean companies to leverage their technological strengths and identify synergistic collaboration opportunities. We are committed to intensifying our tailored support to meet the evolving needs of Korean enterprises seeking to establish a presence in the European market, and we will dedicate our efforts to ensuring that these engagements translate into tangible successes, including significant technology exports."
KOTRA's proactive engagement at Swiss Biotech Day 2025 signifies a concerted effort to facilitate the entry and growth of Korean biotech companies within the dynamic European market. By leveraging Switzerland's central role in the global biohealth landscape and fostering direct interactions between Korean innovators and European stakeholders, KOTRA aims to unlock new avenues for collaboration, investment, and ultimately, the successful commercialization of Korean biotechnology on the European stage. This strategic initiative holds the promise of not only boosting the Korean bioeconomy but also contributing to advancements in global healthcare through international partnerships.
[Copyright (c) Global Economic Times. All Rights Reserved.]
